Literature DB >> 35034150

Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide.

Jiangchuan Long1, Yongjian Liu1, Yaqian Duan1, Yang Li1, Gangyi Yang1, Ziyu Ren1, Wei Tao2, Dongfang Liu3,4.   

Abstract

PURPOSE: Gastrointestinal adverse reactions (GIARs) to liraglutide exhibit significant individual differences in type 2 diabetes. This study investigated the association between glucagon-like peptide-1 receptor (GLP-1R) single-nucleotide polymorphisms (SNPs) and GIARs.
METHODS: Adverse events of liraglutide were observed in 376 T2DM patients. Seven tag SNPs at GLP-1R were sequenced in 152 participants. The influencing factors of GIARs and the genetic model of tag SNPs were examined by logistic regression analysis. The relationship between the tag SNPs and GIARs was determined by the chi-square test and cochran-armitage trend test. Multifactor dimensionality reduction (MDR) analysis was used to explore interactive analysis in GIARs risk.
RESULTS: Twenty-nine percent of subjects had side effects, mainly GIARs. Nausea was the most common GIARs. Compared with males, females were more likely to develop GIARs (P = 0.043, OR = 1.895, 95% CI: 1.021-3.517). The T allele at GLP-1R rs2254336 (P = 0.028) and the A allele at GLP-1R rs3765467 (P = 0.007) were associated with GIARs of liraglutide. As the number of rs2254336 T alleles (P = 0.014) or rs3765467 A alleles (P = 0.008) increased, the subjects tended to develop GIARs. MDR analysis identified that there were no significant interactions among rs2254336, rs3765467 and sex.
CONCLUSION: Our results suggest that female sex, the T allele at GLP-1R rs2254336 and the A allele at GLP-1R rs3765467 could be predictors of GIARs with liraglutide in T2DM patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Gastrointestinal adverse reaction; Glucagon-like peptide-1 receptor; Liraglutide; Single-nucleotide polymorphism; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2022        PMID: 35034150     DOI: 10.1007/s00228-021-03225-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

Review 1.  The glucagon-like peptides.

Authors:  T J Kieffer; J F Habener
Journal:  Endocr Rev       Date:  1999-12       Impact factor: 19.871

2.  A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins.

Authors:  M Javorský; I Gotthardová; L Klimčáková; M Kvapil; J Židzik; Z Schroner; P Doubravová; I Gala; I Dravecká; I Tkáč
Journal:  Diabetes Obes Metab       Date:  2016-06-07       Impact factor: 6.577

3.  Diabetic factors associated with gastrointestinal symptoms in patients with type 2 diabetes.

Authors:  Jeong Hwan Kim; Hyung Seok Park; Soon Young Ko; Sung Noh Hong; In-Kyung Sung; Chan Sub Shim; Kee-Ho Song; Dong-Lim Kim; Sook Kyung Kim; Jeeyoung Oh
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

Review 4.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

Authors:  Francesco Cosentino; Peter J Grant; Victor Aboyans; Clifford J Bailey; Antonio Ceriello; Victoria Delgado; Massimo Federici; Gerasimos Filippatos; Diederick E Grobbee; Tina Birgitte Hansen; Heikki V Huikuri; Isabelle Johansson; Peter Jüni; Maddalena Lettino; Nikolaus Marx; Linda G Mellbin; Carl J Östgren; Bianca Rocca; Marco Roffi; Naveed Sattar; Petar M Seferović; Miguel Sousa-Uva; Paul Valensi; David C Wheeler
Journal:  Eur Heart J       Date:  2020-01-07       Impact factor: 29.983

5.  Association Between eNOS, MMP-9, BAG-6 Gene Polymorphisms and Risk of Hypertensive Disorders of Pregnancy in the Northern Chinese Population.

Authors:  Xiaolei Yuan; Man Guo; Yan Li; Yujing Han; Peiling Li
Journal:  DNA Cell Biol       Date:  2020-12-22       Impact factor: 3.311

6.  Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study.

Authors:  Airani Sathananthan; Chiara Dalla Man; Francesco Micheletto; Alan R Zinsmeister; Michael Camilleri; Paula D Giesler; Jeanette M Laugen; Gianna Toffolo; Robert A Rizza; Claudio Cobelli; Adrian Vella
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 19.112

7.  GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.

Authors:  Olivia M Farr; Michail Sofopoulos; Michael A Tsoukas; Fadime Dincer; Bindiya Thakkar; Ayse Sahin-Efe; Andreas Filippaios; Jennifer Bowers; Alexandra Srnka; Anna Gavrieli; Byung-Joon Ko; Chrysoula Liakou; Nickole Kanyuch; Sofia Tseleni-Balafouta; Christos S Mantzoros
Journal:  Diabetologia       Date:  2016-02-01       Impact factor: 10.122

8.  Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study.

Authors:  Yongze Li; Di Teng; Xiaoguang Shi; Guijun Qin; Yingfen Qin; Huibiao Quan; Bingyin Shi; Hui Sun; Jianming Ba; Bing Chen; Jianling Du; Lanjie He; Xiaoyang Lai; Yanbo Li; Haiyi Chi; Eryuan Liao; Chao Liu; Libin Liu; Xulei Tang; Nanwei Tong; Guixia Wang; Jin-An Zhang; Youmin Wang; Yuanming Xue; Li Yan; Jing Yang; Lihui Yang; Yongli Yao; Zhen Ye; Qiao Zhang; Lihui Zhang; Jun Zhu; Mei Zhu; Guang Ning; Yiming Mu; Jiajun Zhao; Weiping Teng; Zhongyan Shan
Journal:  BMJ       Date:  2020-04-28
  8 in total
  1 in total

Review 1.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.